New Depression Treatment Combines Amino Acid Supplement With Therapy—Here's What the Research Shows

A major new clinical trial is testing two non-medication approaches to treating depression in teens and young adults: an amino acid supplement called N-acetylcysteine (NAC) and a structured form of therapy called mindfulness-based cognitive therapy (MBCT). The University of Cincinnati study, funded by approximately $3.5 million from the National Institutes of Health's National Center for Complementary and Integrative Health, represents a shift toward exploring lower-risk alternatives to conventional psychiatric treatments.

What Are These Two Depression Treatments?

The trial combines two distinct interventions that work through different mechanisms. NAC is an amino acid supplement that has been used safely for over 30 years to treat various medical conditions and is now being studied for psychiatric disorders including depression. MBCT, meanwhile, is a structured psychotherapy approach that teaches patients to train their minds to be more mindful while actively challenging negative thought patterns to influence their emotions.

"We are opening up an array of interventions that can be newer, more innovative and lower risk than conventional treatments we have been using," said Dr.Fabiano Nery, the trial's principal investigator and associate professor in the Department of Psychiatry and Behavioral Neuroscience at UC's College of Medicine.

Why Focus on These Approaches for Young People?

Depression in teens and young adults often follows a pattern of recurring episodes, making relapse prevention a critical goal. Traditional medication-based approaches work for many people, but researchers are increasingly interested in complementary options that may carry fewer side effects or risks. This trial specifically targets young adults because they represent a population that may benefit from early intervention with alternative approaches before more intensive treatments become necessary.

What Does the Research Say About These Treatments?

MBCT has already demonstrated effectiveness in clinical settings. According to Dr.Nery, "MBCT has been shown to be very good for people with depression, especially those that have had a lot of episodes. It helps them to decrease relapses in depression, to get them stable, but it has also been shown to help decrease anxiety, to decrease irritability and to improve depressive symptoms". This means the therapy targets not just depression itself but related mental health challenges that often accompany it.

NAC is less established for psychiatric use but shows promise. The supplement works at a cellular level and has been safely used in medical practice for decades, which makes it a lower-risk option to test in a clinical trial setting. By combining NAC with MBCT, researchers hope to understand whether these two approaches work better together or separately.

How to Participate in Depression Treatment Research

• Eligibility Requirements: The trial is open to teens and young adults with depression. Specific age ranges and symptom severity criteria apply, so interested individuals should review full eligibility details.
• Contact Information: Potential participants can reach trial coordinator Khalid Yusuf at 513-558-5479 or yusufkd@ucmail.uc.edu to learn more about the study.
• Online Screening: Interested individuals can complete an online screening questionnaire to determine if they meet study criteria and move forward with enrollment.

What Makes This Trial Different?

This research represents a broader shift in mental health treatment. Rather than relying solely on medications, which can have side effects like weight gain, sexual dysfunction, or emotional blunting, researchers are investigating whether non-pharmacological approaches can be equally or more effective for certain populations. The $3.5 million NIH funding reflects growing recognition that complementary and integrative health approaches deserve rigorous scientific testing.

The trial is particularly timely given that depression rates among young people have risen significantly in recent years. Having multiple evidence-based treatment options—especially ones with lower risk profiles—could expand access to care and improve outcomes for teens and young adults who might otherwise delay seeking help due to concerns about medication side effects.

For those interested in participating or learning more, the University of Cincinnati is actively recruiting participants. The trial will provide valuable data on whether NAC and MBCT can become standard options in depression treatment protocols, potentially offering young people more choices in their mental health care journey.